From Financial Modeling Prep: 2025-03-11 07:00:06

AnaptysBio, Inc. is a biotech company focusing on antibody therapeutics for inflammation and immuno-oncology. Its ROIC is -26.21% with a WACC of 4.92%, resulting in a negative ROIC to WACC ratio of -5.32. Peers like Deciphera, Crinetics, Rhythm, Kura, and CytomX face similar challenges in generating returns above their cost of capital.

Deciphera Pharmaceuticals has a ROIC of -60.55% and a WACC of 5.15%, leading to a ROIC to WACC ratio of -11.75. Crinetics Pharmaceuticals has a slightly better ratio of -3.67, while Rhythm Pharmaceuticals and Kura Oncology struggle with -6.20 and -3.14 ratios, respectively. These companies are not efficiently using their capital.

In contrast, CytomX Therapeutics has a positive ROIC of 62.20% and a ratio of 8.24, indicating effective capital utilization. Among its peers, CytomX stands out as the most efficient in generating returns above its cost of capital, making it an appealing option for investors interested in the biotechnology sector.



Read more at Financial Modeling Prep:: AnaptysBio, Inc. (NASDAQ:ANAB) and Its Competitive Landscape in Biotechnology